ClinicalTrials.gg
RecruitingNCT07617285Updated Jun 1, 2026

Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

A Phase 1 interventional study of CAR-T cells chimeric antigen receptor T cells in AML and Refractory/Relapse Acute Myeloid Leukemia, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Peking University People's Hospital · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital — 15 open to participants now, 16 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · Peking University People's Hospital.

Planned enrollment
13th of 17
27 · median 52
Started
2026
with 6 others
Phase 1
4 of 20
2 open now
Primary completion
2027-12
later than 11 of 15 live
Registered
19th of 20
by date

Among the 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital, this one is the 13th largest by planned enrollment of the 17 interventional ones that give a count, is one of 7 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 11 of the 15 other live ones, and was the 19th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

15 of the 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Leukemia, Myeloid, Acute by Peking University People's Hospital, or all of them as a file.
02

Study summary

A Clinical Study to Investigate the Safety and Efficacy of CT0890B in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Read the detailed description

This is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety, efficacy, and cellular pharmacokinetics of CT0890B in patients with relapsed or refractory acute myeloid leukemia. It is planned to enroll 12\~27 participants in this trial.

03

Conditions studied

  • AML
  • Refractory/Relapse Acute Myeloid Leukemia

Keywords

  • CT0890B
  • Universal CAR-T
  • AML
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-70 years (inclusive), male or female.
  2. acute myeloid leukemia (R/R AML) diagnosed according to the 2022 World Health Organization classification or ELN criteria, with confirmed NKG2D ligand-positive disease.
  3. Bone marrow blasts ≥5% by morphology.
  4. Estimated >12 weeks.
  5. (ECOG) performance status of 0-2.
  6. Adequate organ function without ongoing supportive care, defined as:

    1. Cardiac: (LVEF) ≥50%;
    2. Hepatic: and AST ≤2.5 × (ULN), and total ≤2 × ULN;
    3. Renal: ≥30 mL/min (calculated using the Cockcroft-Gault formula);
    4. Coagulation: (APTT) ≤1.5 × ULN and prothrombin time (PT) ≤1.5 × ULN.

    c) Renal: creatinine clearance ≥30 mL/min (calculated using the Cockcroft-Gault formula); d) Coagulation: activated partial thromboplastin time (APTT) ≤1.5 × ULN and prothrombin time (PT) ≤1.5 × ULN.

Exclusion criteria

Exclusion Criteria:

  1. Participants were diagnosed with acute promyelocytic leukemia (APL), BCR-ABL positive leukemia (chronic myeloid leukemia in acute phase), central nervous system leukemia;
  2. Participants with a history of epilepsy or other central nervous system disease;
  3. Participants who have previously received autologous or allogeneic CAR-T therapy;
  4. Participants who have received stem cell transplantation or allogeneic stem cell transplantation within 12 weeks
  5. Participants who have received prior immunotherapy targeting NKG2DL;
  6. Participant has active or is receiving systemic for GVHD;
  7. Participant has any of the following at screening:

1)Active, uncontrolled systemic infection or requiring intravenous anti-infective agents 2)Any of the following cardiac conditions, including:

  1. Class III-IV heart failure;
  2. History of myocardial infarction, coronary artery bypass grafting, or unstable angina within 6 months prior to Qinglin;
  3. History of uncontrolled arrhythmia of significant clinical significance (as judged by the investigator), such as ventricular arrhythmia;
  4. History of severe nonischemic ardiomyopathy;
  5. Other cardiac disease that the investigatorbelieve could jeopardize the participant 's well-being or compromise participation in this clinical trial; 3) Active bleeding of clinical significance as judged by the investigator; 4)Requiring supplemental oxygen to maintain oxygen saturation> 92%; 5)Patients with severe (COPD) or other lung diseases that cannot tolerate CAR-T treatment as judged by the investigator;
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    CAR-T cells chimeric antigen receptor T cells

    CT0890B cells infusion

    Drug: CAR-T cells chimeric antigen receptor T cells

Interventions

  • DrugCAR-T cells chimeric antigen receptor T cells

    Conditioning regimen: Days -9 to -3: Venetoclax administered with a target dose of 200 mg/day. Days -5 to -4: Cytarabine administered at 500 mg/m²/day. Days -5 to -3: Cyclophosphamide at 300 mg/m²/day plus Fludarabine at 30 mg/m²/day. Day 0: Infusion of CT0890B CAR-T cells at one of four dose levels using an i3+3 Dose-Escalation Design: 1.5 × 10⁸ total cells, 3.0 × 10⁸ total cells, 4.5 × 10⁸ total cells, 6.0 × 10⁸ total cells

    Also known as: Off-the-shelf allogeneic CAR-T cells

06

What researchers measure

Primary outcomes

  1. Adverse Events (AE) after CT0890B infusion

    An assessment of severity grade will be made according to the National Cancer Institute Common Terminology Criteria

    Time frame: 12 months after CT890B infusion

  2. Dose-limiting toxicity (DLT)

    The DLT is evaluated as the proportion of patients who experienced adverse events related to CT0890B that meet the criteria for DLT events after the first infusion

    Time frame: Up to 28 days after CAR-T cells infusion

  3. MTD and/or dose range

    Evaluate Dose limited toxicity and recommended dosage range after CT0890B infusion

    Time frame: Up to 28 days after CAR-T cells infusion

Secondary outcomes

  1. Composite response (CRc)

    The composite response rate (CRc) included complete response (CR), complete response with partial hematologic recovery (CRh), complete response with incomplete hematologic recovery (CRi), and morphologic leukemia-free state (MLFS). Responses were assessed in accordance with the Technical Guidelines for Clinical Development of New Drugs for Acute Myeloid Leukemia and the 2022 European LeukemiaNet criteria for acute myeloid leukemia (AML).

    Time frame: 12 months after CT0890B infusion

  2. Partial response (PR)

    Partial response (PR) was defined and assessed according to the Technical Guidelines for Clinical Development of New Drugs for Acute Myeloid Leukemia and the 2022 European LeukemiaNet response criteria for AML.

    Time frame: 12 months after CT0890B infusion

  3. Rate of Subsequent Stem Cell Transplantation After CAR-T Therapy

    This secondary endpoint was defined as the proportion of patients who proceeded to stem cell transplantation after CAR-T therapy during the study period.

    Time frame: 12 months after CT0890B infusion

  4. Duration of response (DOR)

    Patients achieving CR, CRi, CRh, or MLFS were included in the duration of response (DOR) analysis set. DOR was defined as the time from the date of first documented response to the date of disease relapse or death from any cause, whichever occurred first.

    Time frame: 12 months after CT0890B infusion

  5. Event-free survival (EFS)

    EFS was defined as the time from the date of CAR-T infusion to the earliest occurrence of treatment failure, relapse, or death from any cause. Treatment failure was defined as failure to achieve CR, CRh, CRi, MLFS, or PR at both prespecified efficacy assessments. Relapse included hematologic or extramedullary relapse after achieving CR, CRh, CRi or MLFS. For patients with treatment failure (ineffective therapy), the primary EFS analysis assigned an event time of 1 day (i.e., the time from infusion to treatment receipt). Sensitivity analyses were performed using alternative definitions of event timing, including the actual date of treatment failure, the end of treatment, or the initiation of subsequent anti-leukemia therapy.

    Time frame: 12 months after CT0890B infusion

  6. Overall survival (OS)

    OS is defined as the time from the date of receiving the infusion to the date of death from any cause.

    Time frame: 12 months after CT0890B infusion

  7. Minimal Residual Disease (MRD) Negativity Rate

    MRD negativity rate was assessed in participants who achieved CR, CRh, CRi or MLFS. MRD negativity was defined as \<0.01% abnormal cells among CD45-positive cells as determined by multiparameter flow cytometry (MFC).

    Time frame: 12 months after CT0890B infusion

  8. Pharmacokinetic Endpoint - Peak expansion (Cmax)

    The maximum concentration or peak value of CT0890B cells in plasma after infusion, measured by CAR copy number.

    Time frame: 12 months after CT0890B infusion

  9. Time to peak expansion (Tmax) of CT0890B

    The time required to reach the peak expansion (maximum CAR copy number) in plasma following the infusion of CT0890B cells.

    Time frame: 12 months after CT0890B infusion

  10. Area under the curve (AUC) of CT0890B

    The total cellular exposure in plasma after infusion, calculated based on the area under the CAR copy number-time curve.

    Time frame: 12 months after CT0890B infusion

  11. In vivo persistence of CT0890B

    The duration for which CT0890B cells remain detectable in the plasma after infusion, monitored via CAR copy number.

    Time frame: Up to 12 months after CT0890B infusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Dec 2027, 19 months later.

Of 307 non-industry phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 87. This study's planned 19 months is below that.

Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2026
First posted
Jun 1, 2026
StartEst.
May 7, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2029
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07617285
Collaborators
CARsgen Therapeutics Co., Ltd.
Responsible party
Xiangyu Zhao (Principal Investigator, Peking University People's Hospital) — Principal investigator
First posted
Jun 1, 2026
Start date
May 7, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jun 1, 2026

Study contacts

Xiangyu Zhao, M.D,Ph.D
Contact
Zhao_xy@bjmu.edu.cn
010-88325531
Meng Lv, M.D., Ph.D
Contact
drlvmeng@bjmu.edu.cn
010-88316617
XiangYu Zhao, M.D, Ph.D
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion